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Abstract: Purpose: To investigate the experiences of adults living with 
chronic myeloid leukaemia and treated with tyrosine kinase inhibitors, 
with particular reference to factors influencing adherence. 
Methods: A thematic synthesis of all published qualitative studies 
examining adults with chronic myeloid leukaemia, receiving tyrosine 
kinase inhibitors. Eligible publications were identified by searching 
five electronic databases using defined criteria. The synthesis involved 
complete coding of extracted data and inductive theme development. 
Results: Nine studies were included and three overarching themes defined. 
Overarching themes were: 1) Disease impacts whole life; 2) Disease 
management strategies; and 3) Valued aspects of care. Side-effects often 
required physical and psychological adaptation. Patients developed 
individual decision-making processes to promote adherence and manage side 
effects. Unintentional non-adherence occurred due to forgetfulness and 
system failures. Intentional omission also occurred, which together with 
side effects, was unlikely to be reported to healthcare professionals 
(HCPs). HCP reassurance about missed doses could reinforce non-adherence. 
Information needs varied over time and between individuals. Knowledge 
among patients about treatment was often lacking and could lead to 
misunderstandings. Patients valued psychological support from HCPs and 
suggested an individualised approach, facilitating discussion of 
symptoms, adherence and their perspectives about living with chronic 
myeloid leukaemia, would improve care. 
Conclusions: Patients with chronic myeloid leukaemia experienced 
significant side-effects from treatment and changes to their 
psychological and physical well-being. They developed their own 
strategies to manage their disease and treatment. This should be 
recognised in interventions to improve education, support and the 
delivery of care that is compassionate and adequately resourced. 
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Word count 
6,635 (including quotations) 
Was ethical approval given 
and by whom? (give any 
reference number) 
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Title 
&RQILUPWKDWWKHWLWOHLVLQWKHIRUPDWµ7RSLFTXHVWLRQGHVLJQW\SHRISDSHU¶DQG
identifies the population / care setting studied. 
(e.g. The effectiveness of telephone follow-up in managing symptoms after breast 
cancer radiotherapy: a randomised controlled trial). The structure is optional for 
discussion papers, editorials and letters) 
¥ 
Abstract 
A structured abstract appropriate to the design of the study is included (see guidelines 
for authors).  
¥ 
 
No references are cited in the abstract. ¥ 
Key words 
Between four and ten key words have been provided in alphabetical order, which 
accurately identify the paper's subject, purpose, method and focus. Use the Medical 
Subject Headings (MeSH®) thesaurus or Cumulative Index to Nursing and Allied Health 
(CINAHL) headings where possible (see http://www.nlm.nih.gov/mesh/meshhome.html). 
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Highlights 
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for Authors, does not apply to editorials or letters) 
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below) 
N/A 
 
Please provide references of ANY other papers using data from the study that this 
paper is based on) below. 
N/A 
 
The study is referred to by a distinctive name which will be used in any future 
publications to identify that it is the same study (e.g. RN4Cast) 
N/A 
Authorship 
All authors and contributors sufficiently acknowledged as per Guide for Authors. ¥ 
 
 
 
 
 
PART 2  
Standards of reporting 
Observational cohort, case control and cross sectional studies 
Quasi experimental / non-randomized evaluations 
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Study of Diagnostic accuracy / assessment scale 
Systematic Review of Controlled Trials 
Systematic Review of Observational Studies 
Qualitative studies 
Clinical Practice guidelines 
Other (please give source): Qualitative synthesis 
Then ENTREQ statement was used as a reporting guideline as directed by the EQUATOR network for use in 
qualitative syntheses. This an attached document. 
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ENTREQ reporting statement 
 
Title: Experiences of living with chronic myeloid leukaemia and adhering to tyrosine kinase 
inhibitors: A thematic synthesis of qualitative studies  
 
1: Aim 
To synthesise qualitative research studies investigating the experiences of adults living with 
chronic myeloid leukaemia (CML) and treated with tyrosine kinase inhibitors (TKIs), with 
particular reference to adherence and the factors influencing this. (Introduction pages 2-3) 
 
2: Synthesis methodology 
Thematic synthesis informed by Thomas and Harden (2008) and Braun and Clarke (2013) 
FKRVHQGXHWRLW¶VSUDJPDWLFDSSURDFKWRLQIRUPKHDOWKFDUHSUDFWLWLRQHUVSUDFWLFH0HWKRGV
page 3). 
 
3: Approach to searching 
A pre-planned, systematic and comprehensive search was carried out (Search strategy, 
eligibility and screening, (pages 3-4) 
 
4: Inclusion criteria 
Inclusion and exclusion criteria specified prior to carrying out the search for studies (Table 1: 
eligibility criteria, page 3-4 and 25) 
 
5: Data sources 
Five databases were used to carry out the search, these and the date of searching are 
specified in the search strategy (Search strategy, eligibility and screening, page 3-4). 
Justification for using these databases: well known, comprehensive and relevant data bases, 
agreed by research team based on their experience. 
 
6: Electronic search strategy 
6HDUFKWHUPVXVHGZHUHDVIROORZV³FKURQLF myeloid leukaemia or chronic myeloid leukemia 
or leukaemia myelogenous chronic BCR-$%/SRVLWLYH´DQG³patient satisfaction or patient 
experience or TXDOLWDWLYHUHVHDUFK´No search limits were used. 
 
7: Study screening results 
Five publications were identified in the first search, of which two were included. Citation 
searches led to the screening of 99 additional studies and inclusion of two. Four papers were 
found to be eligible via alerts and one more found via reference search of these alert articles 
(up to September 2019), giving a total of nine included publications.  (Search strategy, 
eligibility and screening pages 3-4 and figure 1 page 25).  
*Standards of Reporting Checklist
8: Study characteristics 
Studies were published between 2011 and 2018. Studies collected data in Europe, Africa, 
Australia and South East Asia; and used various qualitative methods, including ethnography, 
interpretative phenomenological analysis and grounded theory. Characteristics of the studies 
are summarised in Table 2: summary of included studies (pages 26-28). 
 
9: Study selection results 
The search strategy led to the screening of 99 additional studies and inclusion of two. Four 
papers were found to be eligible via alerts and one more found via reference search of these 
alert articles (up to September 2019), giving a total of nine included publications.  Studies 
were excluded based on the eligibility criteria. (Search strategy, eligibility and screening 
pages 3-4).  
 
10: Rationale for appraisal 
As above. Hawker et al (2002) was used as an appraisal tool based on considerations 
suggested by Noyes et al (2018) and suited this synthesis as it is widely cited, simple to 
follow and can accommodate studies with differing methodologies (Search strategy, eligibility 
and screening pages 3-4). 
 
11: Appraisal items 
Included studies were appraised for quality using the tool developed by Hawker et al (2002), 
which incorporated an assessment of abstract and title, introduction and aims, methods 
analysis, ethics, results, transferability and implications (Search strategy, eligibility and 
screening pages 3-4).  
 
12: Appraisal process 
Included studies were appraised for quality by two researchers until consensus achieved 
(Search strategy, eligibility and screening pages 3-4). 
 
13: Appraisal results 
No articles were excluded from the synthesis based on the quality appraisal and no 
weighting was given to studies based on this appraisal. Strengths and weaknesses seemed 
quite evenly spread throughout the articles. 
 
14: Data extraction 
Data was extracted regardless of the section of the article to include: participant quotes, 
researcher summaries, analytical concepts and interpretations. Data was extracted by hand 
then uploaded onto a software programme (NVIVO) (data extraction and coding, page 4). 
15: Software 
NVIVO software was used as a retrieval tool for theme development (data extraction and 
coding, page 4). 
 
16: Number of reviewers 
Coding and themes were developed by a single researcher based on similarities and 
differences between codes and the coding frame independently assessed by a second 
researcher (data extraction and coding, page 4). 
 
17: Coding 
Complete coding of extracted data was carried out. This was done by hand with text 
highlighted and annotated prior to the generation of codes/sub-codes. (data extraction and 
coding, page 4). 
 
18: Study comparison 
Themes were developed inductively and based on similarities and differences between 
codes, with figurative meaning sought via visual mapping and iterative checking (data 
extraction and coding, page 4). 
 
19: Derivation of themes 
Themes were developed inductively (data extraction and coding, page 4). 
 
20: Quotations 
The majority of quotations are direct patient quotes, some were author summaries of patient 
accounts, or their interpretations and these were clearly indicated in the text (results pages 
5-14). 
 
21: Synthesis output 
Analysis of the results is presented in the discussion section. New insight and 
understanding, unmet need and implications for practice and future research are provided 
(discussion, pages 14-16)   
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We would like to thank the reviewers for their comments.  They have helped us improve the paper 
and below, we detail how we have responded to their suggestions. 
REVIEWER 1 
Please note, page numbers on the edited word document are also slightly different from the original 
manuscript but accurately reflect where both reviewers comments were based in the original 
manuscript. Changes to the text as a result of Reviewer 1 comments are highlighted in red in the 
edited document 
a)  Some words or turns of sentences are not nicely choosen, which confuses the reader, for 
instance at the end of introduction : « inform (...) patient survival », or in Figure 1 : « citations » 
should be « references », or at discussion section (first sentence of the second paragraph) : « 
techniques » should be « strategies ». An english speaker should maybe read the article entirely to 
avoid those imperfections. Also some sentences are hard to understand and might be cut in half 
(as line 1 page 10,  line 5 page 16, line 28 page 16, ... ). 
x Introduction: page 3, 1st paragraph, last line changed to:   
 “2) generate evidence that can be used to guide clinical practice. inform and improve clinical practice 
and patient survival. ? 
x Methods: P33, figure 1: The reviewer suggested changing  ?citation ? to  ?references ?. Figure 1 has 
been updated to a PRISMA flow diagram and no longer refers to the Scopus database. 
 
x Discussion: P15,  2nd ƉĂƌĂŐƌĂƉŚ ? ůŝŶĞ  ? ?  ?ƚĞĐŚŶŝƋƵĞƐ ? ŚĂƐ ďĞĞŶ ĐŚĂŶŐĞĚ ƚŽ  ?ƐƚƌĂƚĞŐŝĞƐ ? ? ĂƐ
suggested. 
  
x Results: P10, subtheme 2.2 changed to:  
 “ ?Reasons patients did not compensate for missed doses included: thinking the missed dose would 
not affect response; feeling they could judge for themselves whether to change doses; not wanting to 
bother their doctor; or simply being unable to remember if they had taken a tablet or not (Boons et 
Ăů ? ? ? ? ? ? ?ůŝĂƐƐŽŶĞƚĂů ? ? ? ? ? ? ?>ŝŵĞƚĂů ? ? ? ? ? ? ?dĂŶĞƚĂů ? ?   ? ? ?tƵĞƚĂů ? ? ? ? ? ? ? P ? 
x Discussion: P17 second paragraph, changed to:   
 “The studies we included originated from different countries, some of which described systems of 
free access to TKI medication, and others that did not clarify this. However, as all the studies 
*Cover Letter
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stated being in receipt of TKI medication in their inclusion criteria, presumably all participants 
had access to medication. ? 
 
x Discussion P18:  
͞Development of survivorship programmes or other interventions to support self-management in 
CML requires further qualitative research to investigate the experiences of those caring for people 
with CML. This should also examine contextual issues for patients, such as social support, views on 
ŚŽƐƉŝƚĂůĐĂƌĞĂŶĚĚŝƐĞĂƐĞŬŶŽǁůĞĚŐĞ ? 
b) Beginning to read, about adherence it is unclear if the subject of the article is adherence to 
treatment understanding prescribed treatment as medication (TKI are only suggested in abstract) 
or also adherence to other non-medicated treatment. Regarding the Table 1, I understand that TKI 
adherence is the principal adherence which is about, so medication. The article would gained in 
clarity if using the MeSH word « medication adherence ». And for TKI adherence, It should be 
clearly annunced in the title of the article and a minima in the second sentence of the results. 
Thank you for highlighting this. The following changes have been made to clarify that the study is 
concerned with patient experiences of taking TKIs:  
 
x Title: Changed to: ³Experiences of living ? prescribed treatment tyrosine kinase inhibitors ? ? 
 
x Results: P4, 1st paragraph, lines 1-2, changed to:  “ ?receiving imatinib or second line prescribed 
medication TKIs for CML ? 
 
x Theme 1: P5, Subtheme 1.1, 1st sentence changed to:  “^ŝĚĞĞĨĨĞĐƚƐĨƌŽŵ TKI treatment were ? ? 
 
x Theme 1: P5, Subtheme 1.1, last sentence changed to:  “ ?switching to second generation drugs 
TKIs ? 
 
x Theme 1: P6, Subtheme 1.2, line 5 changed to:  “  ?side effects of treatment TKIs ? ? 
 
x Theme 2: P8, Subtheme 2.1, 1st line changed to:  “ ?strategies used to help them take their TKI ? ? ? 
 
x Theme 2: P9, Subtheme 2.2, 1st line changed to:  “ ? omit their TKI medication intentionally ? ? 
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x Theme 2: P9, Subtheme 2.2, line 8 changed to:  “ĨĞĞůŝŶŐďĞƚƚĞƌĂĨƚĞƌŵŝƐƐŝŶŐTKI medication ? ? 
 
x Theme 2: P10, Subtheme 2.3, line 6 changed to:  “ ?issues were cited as a barrier to TKI ? ? 
 
x Theme 3: P14 Subtheme 3.2, line 2 changed to:  “ ?with better advice on TKI treatment ? ? 
 
x Discussion: P15, 1st paragraph, line 2, P13 changed to:  “TKI treatment side effects ? ? 
dŚĞDĞ^,ƚĞƌŵ “ŵĞĚŝĐĂƚŝŽŶĂĚŚĞƌĞŶĐĞ ?ǁĂƐŶŽƚƵƐĞĚin the search strategy because although an 
element of the study was about TKI adherence, we also aimed to capture broader patient 
experiences. P3, aims, now reads:  
 “ ?evidence to help guide clinical practice ? inform and improve clinical practice and patient survival.   
c) For an article in part about medication adherence, it is unbelievable to not refer to WHO Sabate 
2003. Why have you done this choice ? Is it by intentional or unintentional omission ? WHO 
explained medication adherence with the scope of the « whole entire patient », joining the 
concept of QOL try to do too. Working with this fundamental reference would help to propose 
another modeling figure (Figure 2) including 5 dimensions influencing medication adherence. It 
would show that individual management of CML and adherence to TKI is influenced in particular 
by 3 dimensions :  HealthCare system (HCP), Treatment (side effects) and patient dimensions 
(knowledges and perspectives). 
Thank you for highlighting the WHO paper (Sebate et al 2003), which we consulted during the 
synthesis. As noted, this influential document provides an overview of adherence to medication in 
chronic disease, perceiving it as a multidimensional issue, and viewing the patient holistically. This is 
reflected, as follows:  
Introduction: Page 2, final paragraph.  
 “ ?social situation (Gater et al., 2012). As Sebate et al (2003) highlight in their key WHO report, 
viewing the patient as having individual responsibility for adherence ignores the contextual factors 
which impact upon it, such as socioeconomic and health system issues. ? 
x Discussion: Page 15, 3rd paragraph, line 9.  
³The multifactorial nature of non-adherence to medication in chronic disease as a global burden has 
been well described a key WHO report (Sebate et al 2003). ? 
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The WHO model of medication adherence also represents the patient within the context of their life 
illustrating the various factors effecting their adherence. As the reviewer notes, this is directly 
relevant to our synthesis model. However, we adapted our model to the multidimensional nature of 
medication adherence, for the following reasons: 
1) The section of the WHO document (Sebate et al, 2003) on cancer focuses only on adherence to 
palliative medication (e.g. pain relief) rather than medication to treat disease, such as TKIs.  
2) The document was published in 2003 at the beginning of the widespread global use of TKIs, and 
before studies on adherence to TKIs.  
3) The WHO document focuses on living with chronic illness, which does not fully reflect living with 
chronic cancer, including: potential fatality due to non-adherence; the psychological impact of 
leukaemia diagnosis; long-term hospital care and monitoring. 
d) Methods section: Figure 1 is unclear. Would you mind to use flow diagram PRISMA ? It would 
be pertinent to have a figure which explained clearly the reasons of exclusion refering to Table 1. 
Thank you for commenting on Figure 1. We have included a PRISMA flow diagram, as follows:  
Figure 1: Screening process and identification of eligible studies 
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Also, we have altered the text in the Search strategy, eligibility and screening section, P3 as follows: 
 “Initial data base searching and citation searches led to the identification of 104 studies, with 7 
additional papers found via database alerts (up until September 2019). After the removal of 
duplicates, 100 studies were screened and 91 excluded. Nine studies were found to be eligible, were 
summarised (Table 2) and included in the analysis (See Figure 1, PRISMA flow diagram (Liberati et al., 
2009)). ? 
 
e) For the quality of eligible studies (strenghts and weaknesses), it woud be interested to the 
reader to have the « tool » (Hawker et al., 2002) completed in Table or Appendix for each of the 9 
studies. 
We have added a quality appraisal summary (Hawker et al. 2002) for included studies (Table 3, 
below). 
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Table 3: Quality appraisal of included articles, based on Hawker et al (2002) 
Author/year  Abstract/ title Introduction/ aims Methods/ data Sampling Data analysis Ethics/bias Findings Transferability/ generalisability 
Implications/
usefulness 
Eliasson et al 2011 Good Good Fair Fair Fair Fair Good Fair Fair 
Guilhot et al 2013 Good Fair Good Fair Fair Fair Good Fair Fair 
Chen et al 2014 Good Fair Fair Fair Poor Fair Fair Fair Fair 
Wu et al 2015 Fair Good Fair Fair Fair Fair Fair Fair Good 
Bolarinwa et al 2017 Fair Fair Fair Fair Poor Fair Good Fair Fair 
Graffigna et al 2017 Fair Fair Fair Poor Fair Poor Fair Poor Fair 
Lim et al 2017 Good Good Good Fair Poor Fair Fair Good Good 
Tan et al 2017 Good Good Good Fair Fair Fair Good Fair Good 
Boons et al 2018 Fair Fair Fair Fair Poor Fair Good Fair Good 
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f) Results section : A sentence at the beginning of Results section (line 10) « Themes and sub-
themes...clearly marked as such. » depends to Methods section. Would you mind to integrate it to 
« Data extraction and coding » please ? 
For clarity, we have kept the sentence in the Results and also added the following to the Methods 
P4, data extraction and coding, last sentence:  “Themes and sub-themes are reported in the Results, 
represented by patient quotes and excerpts from author-interpretations ? 
g) To gained in clarity (page 13 - first sentence of « 3.2 : Interpersonal and resource-based 
improvements in care ») , please would you mind to precise which papers suggested patient/HCP 
consultations could be more individualised ? 
Results: P14, Section 3.2. 1
st
 paragraph, has been changed to provide specific references as follows: 
 “Several papers suggested patient/HCP consultations could be more open and individualised 
(Eliasson et al., 2011; Graffigna et al., 2017; Wu et al., 2015), with better advice on TKI treatment 
options (Chen et al., 2014; Guilhot et al., 2013), managing side effects (Boons et al., 2018; Guilhot et 
al., 2013; Lim et al., 2017), dealing with omitted doses (Chen et al., 2014; Eliasson et al., 2011; Wu et 
al., 2015), monitoring response (Guilhot et al., 2013) and establishing drug-taking routines (Eliasson 
et al., 2011; Guilhot et al., 2013; Tan et al., 2017) ? (Bolarinwa et al., 2018; Boons et al., 2018; Chen et 
al., 2014; Eliasson et al., 2011; Guilhot et al., 2013; Lim et al., 2017; Tan et al., 2017; Wu et al., 2015). 
h) Discussion section : I don't understand the importance to talk about Grey literature (page 16). 
This is a limitation (not important in my understanding of your article), which have not its space in 
this part of the discussion. 
ThĞ:KE “ŐƵŝĚĞ ĨŽƌĂƵƚŚŽƌƐ ?ƌĞĐŽŵŵĞŶĚƐuse of the International Committee of Medical Journal 
ĚŝƚŽƌƐ ?  “ƵŶŝĨŽƌŵƌĞƋƵŝƌĞŵĞŶƚƐ ĨŽƌŵĂŶƵƐĐƌŝƉƚƐ ƐƵďŵŝƚƚĞĚ ƚŽďŝŽŵĞĚŝĐĂů ũŽƵƌŶĂůƐ ? ?This suggested 
including study limitations in the discussion. We have clarified that  ?grey literature ? is part of this 
section of the discussion, as follows: 
x Discussion: P17, 3rd paragraph:  “The synthesis may be limited by the exclusion of grey literature 
and articles not written in the English language, which could not be fully searched due to time-
constraints; but however, the authors ? ? 
i) After reading this article, some questions stayed without answers : 
-Which are the « certain countries » and « some countries » (page 10) in the Results section « 2.3 
Exteral influences on disease management. » ?  It would be informative to cite those countries, in 
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particular because you discuss about it later. -In the same paragraph, It would be interesting to 
said clearly in which way are the information gaps between specialities. This is an important way 
to improve clinical practice. 
Results: P10, Section 2.3,
, 
1st and 2
nd
 paragraphs, now addresses findings from different countries 
more specifically. Data in Wu et al (2015) from HCPs has been removed (see Reviewer 2, comment 
3). HCPs ? comments about information gaps is now in the Discussion. We also added a patient quote 
to illustrate communication issues relating to disease management: 
͙͞prescription errors, difficulties with pharmacy (Eliasson et al., 2011) or problems accessing 
medication, and in certain countries (Nigeria and Malaysia), the costs of disease monitoring in 
certain countries  (Bolarinwa et al., 2018; Eliasson et al., 2011; Graffigna et al., 2017; Tan et al., 
2017). Communication issues were cited as a barrier to TKI adherence, with some patients unable to 
gain access to advice; HCPs reporting difficulties for patients with limited English; and information 
gaps said to exist between specialities (e.g. pharmacy/HCPs) (Eliasson et al., 2011; Wu et al., 2015)": 
 “ ? ?/ŐƵĞƐƐďĞĐĂƵƐĞǇŽƵĚŽŶ ?ƚǁĂŶƚƚŽŐĞƚƚŽůĚŽĨĨĨŽƌŶ ƚƚĂŬŝŶŐŝƚ ?ǇŽƵŬŶŽǁ ? And [if I take my imatinib 
ŽƌŶŽƚ ?ŝƐŶŽƚƐŽŵĞƚŚŝŶŐ/ ?ǀĞďĞĞŶƐƉĞĐŝĮĐĂůůǇĂƐŬĞĚĞŝƚŚĞƌ ? ? ?ůŝĂƐƐŽŶĞƚĂů ? ? ? ? ? ? ?Ɖ ? ? ? ? 
In some countries (e.g. Nigeria, Malaysia, Brazil and Russia) where TKI provision was not always 
universal, a limited supply of TKIs or out of pocket costs ? ? 
j) After reading this article, some questions stayed without answers : 
 -Which TKI takes patients of those 9 studies ? And so differences of coding schemes are there 
reported ? Is there any differences described in the 9 studies about the duration of 
disease/treatment, and/or age of participants ? Because CML living experience and adherence to 
TKI can be influenced by many external factors (molecules of TKI, duration of disease, age of 
participants, ...), given more information and analysis about it would give better understanding of 
it. 
Studies did not always specify the type of TKI examined, as follows: i) Imatinib: 4 studies; ii) TKI (type 
not reported): 3 studies; iii)  “ĨŝƌƐƚĂŶĚƐĞĐŽŶĚ ůŝŶĞd</Ɛ ? ?  ?ƐƚƵĚǇ; iv) Imatinib or nilotinib: 1 study. 
Treatment duration varied and was not always stated; where reported, this ranged from 3 months to 
7 years. As detailed in Table 3 (was Table 2), age was reported by all studies (range 20-80 years).  
The Results section, P4, first paragraph has been adapted as follows: 
 “Characteristics of the nine included studies are shown in Table 2. All were published 2011-2018 and 
included people receiving imatinib or second line prescribed medication TKIs for CML. Not all studies 
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reported the type of TKI as follows: i) Imatinib: 4 studies; ii) TKI (type not reported): 3 studies; iii) 
 “ĨŝƌƐƚĂŶĚƐĞĐŽŶĚůŝŶĞd</Ɛ ? P ?ƐƚƵĚǇ ?ŝǀ ?/ŵĂƚŝŶŝďŽƌŶŝů ƚŝŶŝď P ?ƐƚƵĚǇ ?Often with the emphasis was on 
ĂĚŚĞƌĞŶĐĞ ? ? 
Although it would be interesting to investigate CML patient experiences by such factors as duration 
or treatment, identification of associations would require larger studies with more detailed 
reporting.  
 REVIEWER 2 
Please note, changes to the text as a result of Reviewer 2 comments are highlighted in green in the 
edited document. Also, page numbers on the edited word document are slightly different from the 
original manuscript but accurately reflect where both reviewers comments were based in the 
original manuscript. 
 
1. I think you should revisit your second aim: do you think that your synthesis actually generated 
(as such) evidence that "informed and improved clinical practice and patient survival"? I would 
just "tone" this claim/ aim down. 
We agree (please also see Reviewer 1, comment a). This now reads: Introduction, P3. First 
paragraph:  
 “2) generate evidence that can be used to guide clinical practice. inform and improve clinical practice 
and patient survival. ? 
 
2. You have indeed been systematic in your approach to collect the evidence - it is a shame that 
you did not include a PRISMA flow diagram. This is the usual reporting tool for gathering evidence, 
so I would suggest you added it in. 
We agree and have included a PRISMA diagram (see Figure 1 above: Reviewer 1, comment d) 
3. You have included a table with eligibility criteria, and nowhere did you state that you would 
include HCP data. Now the study by Wu et al. is a comparative IPA (pushing the methodological 
boundaries) and you have included the dataset for HCPs. You need to follow your study protocol 
and your aim irrespective of how interesting other perspectives can be. Otherwise the question 
raised is whether you included all evidence on HCP perspectives? I would suggest you removed 
any information coming from the HCPs in the results section and use this to enrich your discussion 
section. 
10 
 
This is helpful. We have removed HCP data from Wu et al (2015) (shown in green in the main 
document) and an explanation for this is added to the Results section, P4: 
 “ůůƉƵďůŝĐĂƚŝŽŶƐĐŽŶƚĂŝŶĞĚƉĂƚŝĞŶƚŝŶƚĞƌǀŝĞǁƐĂŶĚŽŶĞŝŶĐůƵĚĞĚŚĞĂůƚŚĐĂƌĞƉƌĂĐƚŝƚŝŽŶĞƌƐ ?,WƐ ? ?tƵ
et al., 2015). Only data from the patient sample in the latter study was used in the synthesis, to 
comply with eligibility criteria ? 
As suggested we have included HCPs perspectives (Wu et al) in the Discussion, as follows: 
Discussion P16, 3
rd
 paragraph:  
 “Additional complexity is introduced by HCPs if they inadvertently provide conflicting or misguided 
advice to patients; are unaware how individuals cope with treatment and side effects; or do not 
provide sufficient or consistent psychological support. Wu et al (2015) highlight complexity of care 
delivery from the perspective of HCPs, with issues such as budget and time restraints preventing 
adequate support, and language issues and miscommunication between hospital departments 
effecting adherence. This study also reports alignment between HCPs and patients regarding the late 
identification of side effects and perceptions of CML as a low maintenance disease. In recognition of 
such complicated pathways and experiences, and the impact of health system factors, Harley et al., 
(2019) ? 
4. You state on page 14 that "the perception of cancer as a chronic disease and the impact of this 
on patient experiences, is not clearly defined". Could you add a statement to explain which 
aspects are not defined? 
We agree with this observation and have re-written the Discussion, P15, 3
rd
 paragraph (shown in 
green), as follows: 
Aspects of self-management in chronic illness, such as adherence to medication are widely 
documented (Velde et al., 2019). The multifactorial nature of non-adherence to medication in chronic 
disease as a global burden has been well described in a key WHO report (Sebate et al 2003) and 
consequent literature. However, in contrast to the consequent complex literature exploring this 
concept in chronic illness (Velde et al., 2019), the perception of cancer as a chronic disease and the 
impact of this on patient experiences, is not clearly defined (Harley et al., 2019; Pizzoli et al., 2019). 
Less well documented are definitions of chronic cancer and patient experiences of chronic cancer, 
including their disease management and hospital care (Harley et al., 2019; Pizzoli et al., 2019).   
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5. Can you describe any limitations related to the studies themselves that could potentially impact 
on your end synthesis product? 
Thank you for noting this. We agree and have amended the Discussion, P17, last paragraph as 
follows: 
 “Included studies (Table 3) also had limitations. Overall, several lacked a thorough reporting of 
methods, particularly sampling strategies (e.g. inclusion criteria and reporting on excluded 
participants), and in the application of theoretical models to data analysis. For example, Wu et al., 
(2015) used interpretative phenomenological analysis (IPA), but did not describe how it ?ƐĨĞĂƚƵƌĞƐ
were implemented in the analysis, including the impact of the researchers' own conceptions on the 
findings. Strengths were mostly in the reporting of results; although this varied from descriptive to 
more conceptual accounts, there was consistency between the data and results, quotations were 
used appropriately, and findings were generally presented clearly. ? 
6. Please include a clear conclusion. 
We agree this is lacking and have added this paragraph to the end of the Discussion, P18: 
 “This synthesis has demonstrated the significant impact CML and TKI treatment have on patient 
wellbeing and day to day life. As with an increasing number of cancers, CML involves the self-
management of treatment at home, outside the clinical environment. Our synthesis provides 
evidence that, in the home-setting, patients develop their own strategies to manage adherence and 
side effects, often not discussing this with HCPs. CML self-management occurs within the context of 
ƚŚĞŝŶĚŝǀŝĚƵĂů ?ƐŽǁŶŬŶŽǁůĞĚŐĞĂŶĚƉĞƌĐĞƉƚions of their disease, as well as the influence of their HCP 
and the nuances of the health system providing care. As in other chronic cancers, little research exists 
about experiences and survivorship in CML, or the perspectives of HCPs. However, given that 
treatment is administered at home, the development of survivorship programmes or interventions 
should perhaps look beyond a medical model of disease management, to a more a community-based 
social model, delivered with the support of primary care teams, in a setting familiar to patients and 
where they live their lives. Such an approach, which has the capacity to adapt to individual contexts 
and choices, may be most appropriate to develop mechanisms for supporting patient decision 
making and disease management strategies. ? 
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Abstract  
 
Purpose: To investigate the experiences of adults living with chronic myeloid leukaemia and 
treated with tyrosine kinase inhibitors, with particular reference to factors influencing 
adherence. 
Methods: A thematic synthesis of all published qualitative studies examining adults with 
chronic myeloid leukaemia, receiving tyrosine kinase inhibitors. Eligible publications were 
identified by searching five electronic databases using defined criteria. The synthesis 
involved complete coding of extracted data and inductive theme development. 
Results: Nine studies were included and three overarching themes defined. Overarching 
themes were: 1) Disease impacts whole life; 2) Disease management strategies; and 3) 
Valued aspects of care. Side-effects often required physical and psychological adaptation. 
Patients developed individual decision-making processes to promote adherence and 
manage side effects. Unintentional non-adherence occurred due to forgetfulness and system 
failures. Intentional omission also occurred, which together with side effects, was unlikely to 
be reported to healthcare professionals (HCPs). HCP reassurance about missed doses 
could reinforce non-adherence. Information needs varied over time and between individuals. 
Knowledge among patients about treatment was often lacking and could lead to 
misunderstandings. Patients valued psychological support from HCPs and suggested an 
individualised approach, facilitating discussion of symptoms, adherence and their 
perspectives about living with chronic myeloid leukaemia, would improve care. 
Conclusions: Patients with chronic myeloid leukaemia experienced significant side-effects 
from treatment and changes to their psychological and physical well-being. They developed 
their own strategies to manage their disease and treatment. This should be recognised in 
interventions to improve education, support and the delivery of care that is compassionate 
and adequately resourced. 
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treated with tyrosine kinase inhibitors, with particular reference to factors influencing 
adherence. 
Methods: A thematic synthesis of all published qualitative studies examining adults with 
chronic myeloid leukaemia, receiving tyrosine kinase inhibitors. Eligible publications were 
identified by searching five electronic databases using defined criteria. The synthesis 
involved complete coding of extracted data and inductive theme development. 
Results: Nine studies were included and three overarching themes defined. Overarching 
themes were: 1) Disease impacts whole life; 2) Disease management strategies; and 3) 
Valued aspects of care. Side-effects often required physical and psychological adaptation. 
Patients developed individual decision-making processes to promote adherence and 
manage side effects. Unintentional non-adherence occurred due to forgetfulness and system 
failures. Intentional omission also occurred, which together with side effects, was unlikely to 
be reported to healthcare professionals. Health care professional advice could reinforce non-
adherence. Information needs varied over time and between individuals. Knowledge among 
patients about treatment was often lacking and could lead to misunderstandings. Patients 
valued psychological support from health care professionals and suggested an individualised 
approach, facilitating discussion of symptoms, adherence and their perspectives about living 
with chronic myeloid leukaemia, would improve care. 
Conclusions: Patients with chronic myeloid leukaemia experienced significant side-effects 
from treatment and changes to their psychological and physical well-being. They developed 
their own strategies to manage their disease and treatment. This should be recognised in 
interventions to improve education, support and the delivery of care that is compassionate 
and adequately resourced. 
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manage side effects. Unintentional non-adherence occurred due to forgetfulness and system 
failures. Intentional omission also occurred, which together with side effects, was unlikely to 
be reported to healthcare professionals (HCPs). HCP reassurance about missed doses 
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Introduction  
Chronic myeloid leukaemia (CML) is a haematological malignancy arising when bone 
marrow stem cells produce excessive and abnormal white cells. Most people with CML have 
the Philadelphia chromosome which carries the defective BCR-ABLΌ gene, enabling 
production of the tyrosine kinase enzyme which stimulates the disease process (Frazer et 
al., 2007). It is characterised by a chronic, accelerated and blast phase, with most diagnoses 
made in the chronic phase and commonly associated with anaemia and splenomegaly 
(Jabbour and Kantarjian, 2018). A rare disease (European incidence 1-2/100,000 
population), with an average age at diagnosis of around 57 years, CML is more common in 
men than women (Brunner et al., 2013; Pulte et al., 2013; Rohrbacher and Hasford, 2009; 
Smith et al., 2011; Visser et al., 2012). Incidence of CML does not differ by ethnic origin, 
geographical region or socioeconomic status (Hehlmann et al., 2007; Smith et al., 2011).  
The introduction of oral tyrosine kinase inhibitors (TKIs: targeted therapies given orally to 
block cancer cell growth) at the turn of the current century transformed CML from a rapidly 
fatal disease, to an illness with a chronic trajectory. Imatinib (or Gleevec/Glivec) was the first 
7.,WREHLQWURGXFHGIROORZHGE\DUDQJHRI µVHFRQGJHQHUDWLRQ¶GUXJV6XUYLYDOKDVVLQFH
improved to the extent that European rates are now similar to those of the general 
SRSXODWLRQ%M|UNKROPHWDO6PLWKHWDO5HVSRQVHWR7.,VLVGHVFULEHGDV³WKH
PRVW LPSRUWDQW SURJQRVWLF IDFWRU´ IRU &0/ PDQDJHPHQW LQ WKH (XURSHDQ /HXNDHPLD1HW
recommendations (Baccarani et al., 2013) and has the greatest effect on survival. 
Importantly, several studies examining treatment have identified a link between adherence 
and response (Almeida et al., 2013; Ganesan et al., 2011; Marin et al., 2010; Noens et al., 
2009), with influencing factors including: drug dose, time since diagnosis, treatment duration, 
comorbidity, clinician/patient relationships and patient understanding of CML (Gater et al., 
2012; Noens et al., 2014). Since more people are living with the long-term effects of CML 
(Atallah and Ritchie, 2018), health related quality of life (HRQOL) and symptom burden have 
gained particular importance. Unfortunately, however, significantly worse outcomes are 
reported in people with CML compared to the general population (Efficace et al., 2011; 
Phillips et al., 2013); a situation which can affect adherence (Marin et al., 2010).  
5HVHDUFKH[DPLQLQJ WKHVH LVVXHVKDVEHHQFULWLFLVHGIRU WDNLQJD³UHGXFWLRQLVWELRPHGLFDO´
approach, measuring only objective predictors of non-adherence (i.e. disease and treatment 
UHODWHGIDFWRUVUDWKHUWKDQLQYHVWLJDWLQJWKHUROHRISDWLHQWV¶EHOLHIVH[SHULHQFHVDQGVRFLDO
situation (Gater et al., 2012). As Sebate et al (2003) highlight in their key World Health 
Organisation (WHO) report, viewing the patient as having individual responsibility for 
adherence ignores contextual factors which impact upon it, such as socioeconomic and 
health system issues. More recently, however, qualitative studies have examined broader 
patient experiences (e.g. Graffigna et al., 2017, Lim et al., 2017). The pragmatic aims of the 
current study are to: 1) explore how individuals perceive and describe their experiences of 
taking long-term TKIs, with particular reference to adherence, side effects and quality of life; 
and 2) generate evidence that can be used to guide clinical practice.  
Methods 
Although the first part of the synthesis is an open question (to explore the CML experience), 
suggesting iterative or interpretive approaches were appropriate (Barnett-Page and Thomas, 
2009; Dixon-Woods et al., 2006, 2005; Paterson, 2012), the second part (to inform clinical 
practice) is more pragmatic. Various methods of qualitative synthesis were investigated to 
find a methodological approach that could incorporate both aspects of the research question, 
with thematic synthesis considered the most appropriate. Thematic synthesis is a realist 
approach, which permits an open research question and also reflects our pragmatic aim. In 
WKLVZD\LWLVFRPSDUDEOHWRWKHLGHDRI³VXEWOHUHDOLVP´+DPPHUVOH\ZKLFKDFFHSWV
that there is a shared reality outside of us, but that one can only know this reality through the 
minds and perspectives of individuals. Other factors, such as researcher experience and 
background, available resources and type of data also suited the thematic synthesis 
approach. Methods were guided by key references (Braun and Clarke, 2013; Thomas and 
Harden, 2008), as recommended (Barnett-Page and Thomas, 2009; Booth et al., 2016; 
Flemming, 2007; Paterson, 2012), and are presented below in accordance with the 
ENhancing Transparency in REporting the synthesis of Qualitative research (ENTREQ) 
statement (Tong et al., 2012). 
Search strategy, eligibility and screening  
$ V\VWHPDWLF VHDUFK RI ³FKURQLF P\HORLG OHXNDHPia or chronic myeloid leukemia or 
leukaemia myelogenous chronic BCR-$%/ SRVLWLYH´ DQG ³patient satisfaction or patient 
experience or TXDOLWDWLYH UHVHDUFK´ ZDV FRQGXFWHG ZLWKLQ 0('/,1( &,1$+/ 3V\F,1)2
Social Sciences Citation Index: Web of Science, and Google Scholar. Electronic alerts were 
set up in each site, with Scopus used to check citations. The initial search was conducted in 
2016, with papers screened for eligibility (see Table 1 for criteria) using the study abstract or 
full text.  
Initial data base searching and citation searches led to the identification of 104 studies, with 
7 additional papers found via database alerts (up until September 2019). After the removal of 
duplicates, 100 studies were screened and 91 removed. Nine studies emerged as eligible, 
as shown in the PRISMA flow chart in Figure 1 (Liberati et al., 2019). Table 2 provides 
summaries of the included studies. Strengths and limitations of eligible studies were 
appraised by two  
researchers (AH, DM) using a quality assessment tool (Hawker et al., 2002). Each study was 
H[DPLQHGXVLQJWKLVWRRO+DZNHUHWDOWRDOORFDWHJUDGLQJVµSRRU¶µIDLU¶DQGµJRRG¶
as shown in Table 3. Strengths were noted in the reporting of findings, which ranged from 
descriptive to conceptual accounts, with quotations being consistent and illustrative of results 
and themes. Weaknesses were noted in most studies: several did not describe the 
relationship between researchers and participants or inclusion/exclusion and sampling 
criteria; others used a theoretical framework but did not report how this was applied during 
data analysis.  
Data extraction and coding 
Extracted data included participant quotations UHVHDUFKHU¶ VXPPDULHV DQG DQDO\WLFDO
concepts and interpretations, which ensured findings were captured clearly (Thomas and 
Harden, 2008). Thematic synthesis involved complete coding of extracted data, with codes 
derived inductively, based on the study aims (Braun and Clarke 2013, Thomas and Harden, 
2008). This was carried out manually (AH), with text highlighted and annotated prior to the 
generation of codes/sub-FRGHVQDPHGWRHQFDSVXODWH³PHDQLQJDQGFRQWHQW´7KRPDVDQG
Harden, 2008). Codes were compared across eligible publications, with new entities created 
and existing fields merged until a coding frame was finalized (Braun and Clarke, 2013). 
Publications and coding schemes were uploaded into NVIVO, which was used as a retrieval 
tool for theme development. Themes were developed inductively (AH), based on similarities 
and differences between codes, with figurative meaning sought via visual mapping and 
iterative checking, independently assessed by a second researcher (DM).  Themes and sub-
themes are reported in the Results, represented by patient quotations and excerpts from 
author-interpretations. 
Results 
Characteristics of the nine included studies are shown in Table 2. All were published 2011-
2018 and included people receiving imatinib or second line TKIs for CML. Not all studies 
reported the type of TKI as follows: i) Imatinib: 4 studies; ii) TKI (type not reported): 3 
VWXGLHV LLL ³ILUVWDQGVHFRQG OLQH7.,V´VWXG\ LY ,PDWLQLERUQLORWLQLEVWXG\ Often the 
emphasis was on adherence, but studies also explored patient perceptions of CML, disease 
stage, disease impact and health-seeking behaviour. All publications contained patient 
interviews and one also included health care practitioners (HCPs) (Wu et al., 2015). Only 
data from the patient sample in the latter study was used in the synthesis, to comply with 
eligibility criteria. Studies were located in Europe, Africa, Australia and South East Asia; and 
used various qualitative methods, including ethnography, interpretative phenomenological 
analysis and grounded theory.  
Thirty-eight codes were generated from included studies with three overarching themes: 1) 
Disease impacts whole life; 2) Disease management strategies; and 3) Valued aspects of 
care; each of which had multiple sub-themes. Themes and sub-themes are reported in the 
following section, with verbatim patient quotations and excerpts from author-interpretations, 
which are clearly marked as such. Themes are also summarised in Figure 2, which 
demonstrates how the initial impact of a CML diagnosis influences the way individuals 
manage their disease and treatment at this time, and the effect of factors arising over the 
life-course, including hospital care, disease awareness and changing perspectives and 
beliefs. Overall, Figure 2 illustrates the individual, situated within the context of what is 
essentially chronic cancer. 
Theme 1: Disease impacts on whole life 
This theme relates to the physical, psychological and practical impacts of living with CML, 
including the effect of this cancer on different areas of life. 
1.1: Side effects  
Side effects from TKI treatment were common and reported as physical or psychological. 
Physical symptoms commonly included nausea and/or vomiting, pain, skin problems and 
fatigue. Medication and disease effects were reported as impacting on daily life, usual 
activities and adherence (Bolarinwa et al., 2018; Boons et al., 2018; Chen et al., 2014; 
Eliasson et al., 2011; Lim et al., 2017; Tan et al., 2017; Wu et al., 2015): 
³7LUHGQHVVRIFRORVVDO\RXNQRZ²,¶YHJRWD\RXQJIDPLO\DQGMXVWVRUWRIWU\LQJWRNHHSXS
with the daily routine of that is noWHDV\´(Wu et al.,2015, p258) 
³,GRQ¶WZDQWWRWDNHLWEHFDXVHLWPDNHVPHIHHOVLFN$QGWKHQH[WGD\,¶GIHHODELWEHWWHU
EHFDXVH,¶GQRWKDGWKHP,FRQVFLRXVO\GLGQ¶WWDNHLW%HFDXVH,GLGQ¶WZDQWWRWDNHLW´
(Eliasson et al 2011, p629) 
Psychological effects included low mood, but also heightened general health awareness and 
changes in self-identity through a lessening of self-efficacy and the change from individual to 
patient (Chen et al., 2014; Graffigna et al., 2017; Guilhot et al., 2013):  
³,ZDVD\RXQJPDQDWWKDWVWDJH,ZDVIXOORIHQHUJ\DQGHQWKXVLDVP)XOORISURMHFWVIRUWKH
future. I felt that I was unbeatable. The diagnosis initially destroyed me and my perceived 
VWUHQJWK´(Graffigna et al., 2017, p2748) 
Side effects could, however, be mild, or managed by switching to second generation TKIs 
(Bolarinwa et al., 2018; Chen et al., 2014; Eliasson et al., 2011; Guilhot et al., 2013; Lim et 
al., 2017). 
1.2: Adapting daily life 
Many areas of life were affected by CML and its treatment; including employment, leisure 
activities and family roles (Bolarinwa et al., 2018; Boons et al., 2018; Chen et al., 2014; 
Eliasson et al., 2011; Graffigna et al., 2017; Guilhot et al., 2013; Lim et al., 2017; Wu et al., 
2015). Practical concerns about employment and financial matters were reported by several 
patients, in relation to side effects of TKIs, the need for frequent hospital appointments or 
stigma relating to the disease (Chen et al., 2014; Graffigna et al., 2017; Guilhot et al., 2013; 
Tan et al., 2017) In response, patients adapted their routines to cope and manage, including 
changing work commitments and/or stopping hobbies (Boons et al., 2018; Chen et al., 2014; 
Eliasson et al., 2011; Graffigna et al., 2017; Guilhot et al., 2013): 
³,FDQZRrk 75%, and that is not a major issue in the sense that health is more important, but 
LWKDVDPDMRULPSDFWRQP\OLIH´%RRQVHWDOS 
Conversely, living with CML was reported as having little impact on daily life by fewer 
patients, often after treatment had started (Chen et al., 2014; Guilhot et al., 2013; Lim et al., 
2017). Patients also described how their disease and treatment affected family and friends 
and how they perceived the practical and psychological support from these groups as vital 
(Graffigna et al., 2017): 
³0\IDPLO\ZDVEDGO\DIIHFWHGE\P\GLVHDVH7KH\ZHUHVKRFNHGDW¿UVWEXWDVWLPHZHQW
E\WKH\EHFDPHVXFKDQLPSRUWDQWVXSSRUWIRUPH´(Graffigna et al., 2017, p. 2747) 
1.3: Changing perspectives  
Only two publications referUHGWRWKHµSDWLHQWMRXUQH\¶*UDIILJQDHWDO*XLOKRWHWDO
2013), although all noted changing perspectives according to time since diagnosis. The early 
post-GLDJQRVWLFSHULRGZDVGHILQHGE\µVKRFN¶µDQ[LRXVDOHUW¶GHVFULEHGDVDKHLJKWHQHG
awaUHQHVVRIWKHLUKHDOWKRUµFULVLV¶ZLWKVRPHSDWLHQWVVD\LQJWKH\IHOWSHVVLPLVWLFDQG
fearful (Graffigna et al., 2017; Guilhot et al., 2013): 
³,K\SHU-scrutinized my body in search of new symptoms or signals that my health was 
worsening. At that stage I ZDVFHUWDLQWKDWµWKHZRUVW¶ZDVVWLOOWRFRPH´(Graffigna et al., 
2017, p2749) 
This was followed by a process of adaptation, involving the dissipation of anxious feelings, 
before disease/treatment acceptance (Bolarinwa et al., 2018; Boons et al., 2018; Chen et al., 
2014; Eliasson et al., 2011; Graffigna et al., 2017; Guilhot et al., 2013; Lim et al., 2017; Wu 
et al., 2015). Adaptation was an active process, involving growing knowledge and 
understanding of disease, increased awareness of blood results showing treatment 
response, and activity adjustments:  
µµ,WZDVDOODERXWWKHFKLOGUHQEHIRUHHGXFDWLQJDQGGUHVVLQJWKHP«1RZ,SD\DWWHQWLRQWR
myself more. I listen to myself and to what my body VD\V´(Guilhot et al., 2013, p89) 
One study reported patients finding it easier to talk about their disease once they had 
reached acceptance, with people diagnosed more recently saying they found adaptation 
easier, possibly due to the availability of effective treatments, with better prognosis (Guilhot 
et al., 2016RPHSDWLHQWVVDLGWKH\KDGJDLQHGPRUHSRVLWLYHSHUVSHFWLYHVDQGIHOWµOXFN\¶
they had CML rather than a more acute cancer (Bolarinwa et al., 2018; Graffigna et al., 
2017; Guilhot et al., 2013; Wu et al., 2015):  
³7KHUH¶VDORWPRUHSHRSOHZRUVHRIIWKDQPHVR>,@GRQ¶WFRPSODLQWRRPXFK´(Wu et al., 
2015, p259) 
Judging themselves as more fortunate ZDVGHVFULEHGDVµGRZQZDUGFRPSDULVRQ¶DQGZDV
thought to lead to reluctance among some patients to seek help from HCPs (e.g. for side 
effects), (Wu et al., 2015). In contrast, patients also reported continuing feelings of fear and 
sadness:  
³,WKLQN,¶YHDGMXVWHGWR&0/$OWKRXJKWREHKRQHVW,KDYHWRVD\WKDW,VWLOOVRPHWLPHVIHHO
VDG´(Graffigna et al., 2017, p2749) 
Some patients developed a more negative perspective over time due to their experience of 
side effects: 
³,QWKHFRXUVHRIWLPHRIWUHDWPHQWSDWLHQWVGHYHORSHGPRUHQHJDWLYHEHOLHIVDERXW7.,GXH
WRVLGHHIIHFWVHJ³QDVW\SLOOV³DGUDPD´ (Boons et al., 2018, p648, author quotation).  
$VSDWLHQWVDFKLHYHGDµQHZQRUPDO¶*XLOKRWHWDOIROORZLQJDFFHSWDQFHDQG
adaptation, they were said to renew life plans, such as marriage, friendships and hobbies 
(Graffigna et al., 2017; Guilhot et al., 2013). Patients expressed feelings which were 
optimistic, such as hoping to stop treatment in due time (Boons et al., 2018; Graffigna et al., 
2017; Wu et al., 2015), but also feelings of fear for the future (Boons et al., 2018; Chen et al., 
2014; Graffigna et al., 2017; Guilhot et al., 2013): 
³7KHLGHDRIQRORQJHUUHVSRQGLQJLVZRUULVRPHDQG\RXZRQGHUDERXWLWZKHQ\RXKDYHD
FKURQLFGLVHDVH¶¶ (Guilhot et al., 2013, p90) 
 
 
  
Theme 2:  Disease management strategies  
This theme captures patient behaviour (disease management and awareness, adherence, 
management of side effects), at an individual level and in the context of external influences, 
such as practitioner advice and drug availability.  
2.1: Patients have their own management strategies 
Patients described many strategies used to help them take their TKI medication, including 
routine/forward planning, often with family support (Bolarinwa et al., 2018; Boons et al., 
2018; Eliasson et al., 2011; Guilhot et al., 2013; Lim et al., 2017; Wu et al., 2015): 
³0\KXVEDQGUHPLQGVPHWRWDNHP\GUXJ at times my phone ring[s] when it gets to the time 
WRWDNHLW,KDYHQHYHUPLVVHGLW«´(Bolarinwa et al., 2017, p198) 
Patients also developed various techniques to manage symptoms/side effects, such as 
taking medication around mealtimes or before going to bed, to reduce the effects of nausea 
(Chen et al., 2014; Eliasson et al., 2011; Lim et al., 2017; Wu et al., 2015):  
µµ,FKDQJHGWRWDNHWKHPHGLFLQHEHIRUHEHG-time or after a meal. If I take it with an empty 
VWRPDFK,ZLOOGH¿QLWHO\YRPLWLWRXWLQWHQPLQXWHV´(Chen et al., 2014, p124)  
However, whilst data suggest some patients were willing to consult HCPs about disease 
related issues, such as stopping medication, the opposite appeared more common regarding 
side effects or adherence (Eliasson et al., 2011; Lim et al., 2017; Wu et al., 2015); meaning 
that HCPs could be unaware of difficulties. Reasons given by patients for non-consultation 
included reluctance to bother HCPs and/or patients considering their symptoms trivial. 
Similarly, patients were unlikely to inform HCPs about missed medication, thinking it was not 
important, not wanting to upset their doctor, or they could judge themselves whether a 
consultation was required (Eliasson et al., 2011; Lim et al., 2017; Wu et al., 2015): 
³,IRUJRWWRWDNHWKHPHGLFLQHZLWKPH,¶PDOLWWOHELWZRUULHGEXW,VD\QRLW¶VWRRODWHQRZDQG
,GRQ¶WZDQWWRWHOOWKHGRFWRU,GRQ¶WZDQWWRXSVHWWKHGRFWRU´ (Wu et al., p.258) 
 
 ³,ZDVXQDEOHWRKHDUIRUDERXWDZHHNVR,VHOI-DGMXVWHGWKHGRVH«,GLGQRWVeek the 
FRQVXOWDWLRQIURPGRFWRUVEHFDXVHP\QH[WFOLQLFYLVLWZDVPRQWKVDIWHUWKDW´(Lim et al., 
2017, p1927) 
Some patients reported using complementary and alternative medicines to deal with side 
effects or for general health, such as herbal preparations and vitamin supplements 
(Bolarinwa et al., 2018; Wu et al., 2015). Such medicines were also sometimes used as an 
alternative to TKIs for those who held a strong belief in traditional medicine or when 
specialist care coverage was inadequate, causing a delay in diagnosis or interruption in TKI 
treatment (Bolarinwa et al., 2018; Tan et al., 2017): 
³,ZDVYHU\LOO,FRXOGQRWVWDQGDQG,KDYHQREORRGWKDWP\KXVEDQGWRRNPHWRVHYHUDO
KRVSLWDOVDQGKHUEDOLVWKRPHVZLWKQRUHOLHI´ (Bolarinwa et al., 2018, p197) 
2.2: Patients make their own decisions about adherence  
Some patients occasionally decided to omit their TKI medication intentionally, often to avoid 
side effects. This enabled them, for example, to eat and drink normally on social/religious 
occasions or during periods of illness, which could be further complicated by medication that 
involved fasting prior to administration (Bolarinwa et al., 2018; Boons et al., 2018; Chen et 
al., 2014; Eliasson et al., 2011; Lim et al., 2017; Tan et al., 2017; Wu et al., 2015): 
³,WKRXJKWWKHUHZDVQRZD\,ZDVJRLQJ>RQKROLGD\@DQGEHLQJWLUHG6R,GLGDFWXDOO\VWRS
WDNLQJWKHWDEOHWVIRUDZHHNEHIRUH,ZHQW«´(Eliasson et al., 2011, p629) 
Some reported feeling better after missing TKI medication, as side effects were absent 
(Eliasson et al., 2011). Unintentional non-adherence was also reported, commonly due to 
simple forgetfulness, often caused by a change in routine, travelling or social occasions 
(Bolarinwa et al., 2018; Boons et al., 2018; Eliasson et al., 2011; Graffigna et al., 2017; Lim 
et al., 2017; Tan et al., 2017; Wu et al., 2015):  
³0\GUXJLVP\OLIH,WU\WRIROORZWKHGRVDJHRQWKHGRFWRU¶VSUHVFULSWLRQEXWLWPLJKW
VRPHWLPHVKDSSHQWKDW,IRUJHW´(Graffigna et al., 2017, p2746) 
3DWLHQWV¶EHOLHIVDERXWWKHLUPHGLFDWLRQDIIHFWHGPRWLYDWLRQWRDGKHUH%RODULQZDHWDO
Chen et al., 2014; Eliasson et al., 2011; Lim et al., 2017; Wu et al., 2015). Some reported 
IHDURISURJUHVVLRQRWKHUVGHVFULEHGWKHPVHOYHVDVµFRQIRUPLVWV¶ZKRVWULFWO\IROORZHG
PHGLFDODGYLFHRUVDLGWKH\KDGµIDLWK¶LQWKHLUGRFWRUDQGWUHDWPHQW(OLDVVRQHWDO
Wu et al., 2015):  
³,W¶VDEHOLHIUHDOO\WKDW¶VNHHSLQJPHJRLQJ,¶YHQRZSXWDOOP\IDLWKLQ>WKHLPDWLQLE@)URP
GD\RQH,¶YHJRWIDLWKLQ>P\FOLQLFLDQ@´(Eliasson et al., 2011, p629)  
Beliefs and misunderstandings about TKI medication could also result in non-adherence; for 
example, a fear of long-term effects or believing TKIs are only required if symptomatic (Chen 
et al., 2014; Tan et al., 2017): 
³,¶PQRWVXUHDERXWWDNLQJWKLVPHGLFDWLRQ,IHHOZHOO´ (Tan et al., 2017, p1031) 
Whilst some patients adhered because they did not experience side effects, others did so 
despite side effects (Eliasson et al., 2011). Data from one publication suggests adherence 
can change over time (Eliasson et al., 2011) being initially poor as individXDOVµJRWXVHGWR¶
the medication, or decreasing over time, as motivation to adhere decreased, and response 
to medication had been achieved.  
When faced with the decision of how to compensate for missed medication, some said they 
always took their treatment as soon as they remembered (usually the same day), whilst 
others reported not taking missed dose(s). Reasons patients did not compensate for missed 
doses included: thinking the missed dose would not affect response; feeling they could judge 
for themselves whether to change doses; not wanting to bother their doctor; or simply being 
unable to remember if they had taken a tablet or not (Boons et al., 2018; Eliasson et al., 
/LPHWDO7DQHWDO:XHWDO´ 
³,JHWLQWRWKHFDUGXHWRWDNHRIIDQGUHPHPEHUDERXWWKDWDQG,VD\µ$KRQO\RQHGD\¶
GRQ¶WZRUU\DERXWWKDW´(Wu et al., 2015, p258) 
2.3: External influences on disease management 
Decisions about adherence were made within the context of health and social systems. 
Unintentional non-adherence could also be due to prescription errors, difficulties with 
pharmacy (Eliasson et al., 2011) or problems accessing medication, and in certain countries 
(Nigeria and Malaysia), the costs of disease monitoring (Bolarinwa et al., 2018; Tan et al., 
2017). Communication issues were cited as a barrier to TKI adherence, with some patients 
unable to gain access to advice (Eliasson et al., 2011; Wu et al., 2015): 
³,JXHVVEHFDXVH\RXGRQ¶WZDQWWRJHWWROGRIIIRUQRWWDNLQJLW\RXNQRZ$QG>if I take my 
LPDWLQLERUQRW@LVQRWVRPHWKLQJ,¶YHEHHQVSHFL¿FDOO\DVNHGHLWKHU´(OLDVVRQHWDO
p629) 
 
In some countries (e.g. Nigeria, Malaysia, Brazil and Russia), a limited supply of TKIs or out 
of pocket costs, such as laboratory costs and long journeys to hospital appointments, could 
affect adherence (Bolarinwa et al., 2018; Guilhot et al., 2013; Tan et al., 2017): 
³%HIRUH>WKLV@P\EORRGWHVW%&5-ABL is free, now I need to pay hundred[s] over. For private 
>FDUH@ZHVWUXJJOH´ (Tan et al., 2017, p1032) 
Although the synthesis indicated that high levels of adherence are encouraged by HCPs, 
there is also evidence that HCPs may unintentionally reinforce non-adherence by reassuring 
SDWLHQWVWKDW³PLVVLQJWKHRGGGRVH´LVDFFHSWDEOH%RODULQZDHWal., 2018; Eliasson et al., 
2011; Wu et al., 2015): 
³,¶YHPLVVHGDFRXSOHRIQLJKWVDQG,¶YHUDQJOLNHWKHUHVHDUFKQXUVHDQGVKHVDLGµ/RRN
GRQ¶WVWUHVV,W¶VRQO\RQHQLJKW¶´(Wu et al., 2015, p260)  
3DWLHQWVPD\DOVRLQWHUSUHW
VWDEOHUHVSRQVH¶WRPHan missing medication is safe (Bolarinwa 
et al., 2018; Boons et al., 2018; Eliasson et al., 2011):  
³6RPHSDWLHQWVSHUFHLYHGWKDWWKHPLVVHGGRVHZRXOGKDYHQRHIIHFWRQWKHLU7.,UHVSRQVH
and they argued that their haematologist also sometimes said to stop treatment for a period 
ZKHQH[SHULHQFLQJVLGHHIIHFWV«´(Boons et al., 2018, p648, author quotation) 
The extent to which support was provided around adherence and the management of side 
effects differed between publications (Bolarinwa et al., 2018; Boons et al., 2018; Chen et al., 
2014; Eliasson et al., 2011; Guilhot et al., 2013; Wu et al., 2015); and as already noted, 
conflicting advice could be given about missing medication (Eliasson et al., 2011; Wu et al., 
2105):  
³7ZHOYHRXWRISDWLHQWVPDGHFRPments in relation to receiving feedback that seemed to 
KDYHUHLQIRUFHGWKHEHOLHIWKDWµRFFDVLRQDO¶QRQ-DGKHUHQFHGLGQRWPDWWHU´(Eliasson et al., 
2011, p628, author quotation)  
Some data suggest that lack of awareness among HCPs about the extent of non-adherence 
could be due to their reliance on blood-monitoring rather than asking patients (Eliasson et 
al., 2011; Wu et al., 2015). Patients also said little advice was provided about if/how to 
compensate for missed medication and often made this decision themselves (Eliasson et al., 
2011; Lim et al., 2017; Wu et al., 2015). Patients also indicated that advice on managing 
side effects could also be lacking (Boons et al., 2018; Wu et al., 2015): 
³:KHQ,YRPLWHGWKHLQIRUPDWLRQZDVQ¶WWKHUHGR,WDNHDQRWKHU GRVHGRQ¶W,ZLOO,
RYHUGRVH"´(Wu et al., 2015, p260)  
2.4: Varying patient knowledge and information needs over time 
Patient knowledge and understanding was said to influence disease management, including 
side effects, adherence and reporting to HCPs (Chen et al., 2014; Eliasson et al., 2011; 
Graffigna et al., 2017; Lim et al., 2017; Wu et al., 2015). Some patients showed awareness 
about CML. More, however, lacked knowledge, particularly about treatment (Boons et al., 
2018; Chen et al., 2014; Eliasson et al., 2011; Lim et al., 2017; Wu et al., 2015). 
0LVXQGHUVWDQGLQJVLQFOXGHGWKLQNLQJPHGLFDWLRQZDVµVWRUHG¶LQWKHERG\:XHWDO
being unclear on indicators of progression and not fully understanding monitoring: 
³«WKHQXUVHLQVLVWHGWKDW,QHHG WRKDYHDUHJXODUFKHFNWKDW¶VVWUDQJH,FDQ¶WVHHZK\LW¶V
necessary´&KHQHWDOS 
Some patients wanted HCPs to interpret their blood results (Guilhott et al., 2013; Wu et al 
2015), while others preferred to be involved themselves: 
µµ,JHWWKHUHVXOWVSHUVRQDOO\UHDGWKHP¿UVWDQGEULQJWKHPWRP\GRFWRU´(Guilhot et al., 
2013, p85)  
Boons et al (2018) reported that patients expressed a need for information to be current and 
presented in an honest, understandable format, including written material. There was a 
particular need for more information on side effects, including impact on sexuality. Patients 
also wanted more information about hospital appointment systems and social support:  
³,WVKRXOGEHKRQHVW,ZDQWWRNQRZH[DFWO\ZKDWWRH[SHFW´ (Boons et al., 2018, p647) 
*XLOKRWHWDOGHVFULEHGSDWLHQWQHHGIRULQIRUPDWLRQDWHDFKVWDJHLQWKHµ&0/
MRXUQH\¶VD\LQJRQO\EDVLFGLVHDVHWUHDWPHQWXQGHUVWDQGLQJZDVQHHGHGGXULQJWKHLQLWLDO
µFULVLV¶¶VKRFN¶SKDVHZLWKPRUHGHWDLOUHTXLUHGGXULQJµDGDSWDWLRQ¶'LVDSSRLQWPHQWDPRQJVW
patients was noted, concerning how little information clinicians offered at this time: 
³3DWLHQWVVDLGWKDWWKHLU+&3VSURYLGHGOLWWOHWRQRJXLGDQFHRQKRZWRSURSHUO\WDNHWKHLU
therapy and that they implemented their own methods to standardize their drug-taking 
URXWLQHV´(Guilhott et al., 2013, p88, author quotation) 
8SRQUHDFKLQJWKHµQHZQRUPDO¶SDWLHQWV¶DQ[LHWLHVUHGXFHGDQGWKHQHHGIRULQIRUPDWLRQ
was said to be minimal (Guilhott et al., 2013).  
Theme 3: Valued aspects of care 
This theme describes factors valued by people with CML about their care, and potential 
improvements suggested by patients and HCPs. 
3.1: Factors valued by patients and HCPs 
Importantly, rather than education, patients appeared to place greater value on 
psychological support, offered by HCPs who were accessible, had a caring attitude and 
would provide reassurance (Bolarinwa et al., 2018; Boons et al., 2018; Eliasson et al., 2011; 
Guilhot et al., 2013; Lim et al., 2017). 7KHLPSRUWDQFHRIWUXVWDQGµIDLWK¶LQ+&3VZDVDOVR
discussed (Eliasson et al., 2011; Guilhot et al., 2013; Lim et al., 2017):  
³,ZDVVKRFNHGZKHQ,ZDVILUVWGLDJQRVHGZLWKWKLVGLVHDVHEXWP\GRFWRUJDYHPH
encouragement. He assured me that this medicDWLRQZLOOKHOSPHVR,IHOWPRUHUHOD[HG´ 
(Lim et al., 2017, p1927) 
³P\GRFWRUPDNH>V@VXUH,JHWLWHYHQGXULQJGRFWRU¶VVWULNHKHDOVRFDOOVPHWRILQGRXWKRZ,
DPGRLQJ´(Bolarinwa et al., 2018, p197) 
µµ,IHHOWKDW,DPLQYHU\JRRGKDQGV,WUXVWP\GRFWRUIXOO\¶¶(Guilhot et al., 2013, p85) 
Interestingly, more recently diagnosed CML was described by some patients and their HCPs 
DVµORZNH\¶LQWKDWLWZDVDFKURQLFGLVHDVHWUHDWDEOHZLWKORZ-intensity oral medication. 
(Chen et al., 2014; Guilhot et al., 2013 Wu et al., 2015): 
 ³$QRWKHUSDWLHQWZDV³KDSS\NQRZLQJWKHUH¶VDSLOO>VKH@FDQSRS´37QRWLQJWKDWRWKHU
SRWHQWLDOWUHDWPHQWVZHUHDVVRFLDWHGZLWKUHGXFHGHI¿FDF\RUJUHDWHUWR[LFLW\´Wu et al., 
2015, p259) 
 
³7KH¿UVWGRFWRU«VDLGthat it was leukemia but I should not be worried because medicine is 
YHU\GHYHORSHGQRZDGD\V¶¶(Guilhot et al., 2013, p88) 
Whilst this depiction of CML could alleviate anxiety for some, it could also suggest to 
patients that they should be able to manage their CML themselves, thus contributing to 
disinclination to consult HCPs. 
³,FDQMXGJHLWE\P\VHOIDV,NQRZP\FRQGLWLRQYHU\ZHOO,I,KDYHDIOXRUIHYHU,ZLOO
UHGXFHWKHGRVHE\P\VHOI´(Lim et al., 2017, p1927) 
3.2: Interpersonal and resource-based improvements in care  
Several papers suggested patient/HCP consultations could be more open and individualised 
(Eliasson et al., 2011; Graffigna et al., 2017; Wu et al., 2015), with better advice on TKI 
treatment options (Chen et al., 2014; Guilhot et al., 2013), managing side effects (Boons et 
al., 2018; Guilhot et al., 2013; Lim et al., 2017), dealing with omitted doses (Chen et al., 
2014; Eliasson et al., 2011; Wu et al., 2015), monitoring response (Guilhot et al., 2013) and 
establishing drug-taking routines (Eliasson et al., 2011; Guilhot et al., 2013; Tan et al., 2017) 
Supportive, non-MXGJHPHQWDODQGRSHQGLDORJXHWDNLQJDFFRXQWRIWKHSDWLHQW¶VSHUVRQDO
µQDUUDWLYH¶ZDVDOVRUHFRPPHQGHGWRHQFRXUDJHWKHVKDULQJRIDQ[LHWLHVDQGDGKHUHQFH
EHKDYLRXU7KLVUHIOHFWHGSDWLHQWV¶ accounts of what they value in their HCP:  
³«RSHQFRPPXQLFDWLRQZLOOEHEHQH¿FLDOWRWKHSDWLHQWLQWKHPDQDJHPHQWRI&0/
WKURXJKRXWKLVRUKHUMRXUQH\´(Guilhot et al., 2013, p91, author quotation) 
Regarding resources, data indicated that input was lacking from community services, with 
patients saying their General Practitioner (GP) and local pharmacists had little knowledge of 
CML (Eliasson et al., Wu et al., 2015). Suggested improvements included more clinic staff 
and training people with CML as µFRXQVHOORUV¶IRURWKHUSDWLHQWV%RODULQZDHWDO
With respect to facilities and costs, longer-term prescriptions were suggested by both 
patients and HCPs (Chen et al., 2014): 
³DWZR-week schedule just passes too quickly, we should be allowed to have a long-term 
GUXJVXSSO\DQGRQO\FRPHWRYLVLWWKHGRFWRUZKHQZHGRQ¶WIHHOULJKW¶¶ (Chen et al.,2014, 
p124) 
 
Discussion  
The nine qualitative studies included in this thematic synthesis clearly show that CML can 
have a significant impact on physical and psychological well-being and daily activities. TKI 
treatment side effects, traditionally physician assessed and reported as mild to moderate in 
clinical trials (Baccarani et al., 2014; Efficace and Cannella, 2016; Flynn and Atallah, 2016), 
were found to be widespread and disruptive. Interestingly, within work to develop and test 
CML specific patient reported outcomes measures, other authors report that the majority of 
patients with CML experienced persistent symptoms, ranging from mild to severe (Williams 
et al., 2013; ZulbaranǦRojas et al., 2018). It has been suggested that such long-term 
symptom burden may be more difficult to tolerate than intensive treatment, given short-term 
with curative intent (Frick et al., 2017). As previously noted, living with CML is also related to 
significantly worse health related quality of life (HRQOL) (Efficace et al., 2013; Williams et 
al., 2013; ZulbaranǦRojas et al., 2018), than found in the general population (Efficace et al., 
2011; Phillips et al., 2013). In response, validated CML specific HRQOL and symptom 
burden questionnaires have been developed (Efficace et al., 2014; Williams et al., 2013), 
signifying a move away from physician assessed side-effects to patient reported outcome 
measures. 
Our synthesis highlights the chronicity of CML and evidences patients gradually developing  
strategies, beliefs and decision-making processes to manage their disease, adherence and 
side effects; often without consultation with hospital clinicians and sometimes without a 
thorough understanding of their treatment. This is potentially relevant to other cancers 
managed with oral medication, which represents around 25% of all current cancer 
treatments in the United States of America (USA) (Abbott et al., 2014; Weingart et al., 2008). 
This shift from hospital based intravenous therapy to self-managed home treatment has 
many similarities with chronic illnesses, such as diabetes and cardiovascular diseases, 
which also tend to be self-managed.  
Aspects of self-management in chronic illness, such as adherence to medication are widely 
documented (Velde et al., 2019). The multifactorial nature of non-adherence to medication in 
chronic disease as a global burden has been well described in a key WHO report (Sebate et 
al 2003) and consequent literature. Less well documented are definitions of chronic cancer 
and patient experiences of chronic cancer, including their disease management and hospital 
care (Harley et al., 2019; Pizzoli et al., 2019).  Interestingly, patient reluctance to seek 
clinician advice regarding non-adherence and side effects identified in the current study, is 
corroborated in one of few studies on chronic cancer experience (Harley et al., 2019), and a 
large survey highlighting unmet needs among CML patients (Breccia et al., 2015). 
Our study provides insight and understanding into the complexities CML patients face, 
contributing context to what is already known. It highlights how patients may lack knowledge 
about treatment; change their perspective on life; and the influence of HCPs in terms of the 
way they deliver care and advice. Regarding healthcare systems, it describes the possibility 
of hospital errors, pharmacy delay and blood monitoring issues. Other authors suggest 
further complexity due to adherence being underpinned by several factors, including side 
effects, co-morbidities and physician characteristics (Darkow et al., 2007; Marin et al., 2010; 
Noens et al., 2009). The multifactorial nature of chronic cancer symptoms is also said to 
contribute (Frick et al., 2017; ZulbaranǦRojas et al., 2018) with fatigue, for example, relating 
to treatment, but also psychological distress, physical side effects (e.g. pain), and the impact 
of these on daily life (e.g. ability to work) (Efficace et al., 2013; Hofman et al., 2007; 
ZulbaranǦRojas et al., 2018).  
Additional complexity is introduced by HCPs if they inadvertently provide conflicting or 
misguided advice to patients; are unaware how individuals cope with treatment and side 
effects; or do not provide sufficient or consistent psychological support. Wu et al (2015) 
highlight complexity of care delivery from the perspective of HCPs, with issues such as 
budget and time restraints preventing adequate support, and language issues and 
miscommunication between hospital departments effecting adherence. This study also 
reports alignment between HCPs and patients regarding the late identification of side effects 
and perceptions of CML as a low maintenance disease. In recognition of such complicated 
pathways and experiences, and the impact of health system factors, Harley et al., (2019) 
developed the Chronic Cancer Experience Questionnaire (CCEQ), which includes 
multidimensional questions on side effects and daily activities, but also psychological 
wellbeing and the use of clinical services and available support. 
Given the complexity of CML, its increasing prevalence in the TKI era, and emerging 
evidence of unmet needs, it is important that adequate care and support is available during 
long-term survivorship. Although this phase is well documented (Department of Health, 
2013; Mayer et al., 2014; McCabe et al., 2013), much available literature refers to the time-
SHULRGµEH\RQG¶WUHDWPHQWZLWKOLWWOHDGGUHVVLQJH[SHULHQFHVRIµOLYLQJZLWK¶FKURQLFFDQFHUV
whilst taking continual oral medication, as occurs with CML. This concurs with results from a 
study in the USA (Frick et al., 2017), where fewer survivorship care plans were reported for 
patients with chronic cancer (including CML), than for those treated with curative intent.  
Although a review of haematology survivorship models identified a diverse range of 
programmes and suggested primary care HCP involvement (rather than haematology alone 
or another single discipline), the models were said to lack measures of effectiveness (Taylor 
et al., 2015). Unclear professional responsibilities, lack of skills and educational resources, 
and (concurrent with this synthesis), insufficient time, have all been identified as barriers to 
nurses providing adequate care during survivorship for patients with haematological 
malignancies (Langbecker et al., 2016; Wallace et al., 2015). Unfortunately, this is 
associated with a lack of studies addressing self-management interventions for cancer 
patients in general (Howell et al., 2019), despite considerable literature focusing on factors 
effecting self-management and the impact of such interventions in chronic disease (McBain 
et al., 2015; Schulman-Green et al., 2016; Vassilev et al., 2011).  
This is the only qualitative synthesis to generate evidence about experiences of living with 
CML and adhering to prescribed medication. Consequently, we are unable to compare our 
findings with similar work. Major strengths include a robust search strategy, last updated in 
September 2019; inclusion of 320 patients; two researchers checking study eligibility, codes 
and themes; and use of NVIVO computer software to facilitate data management and 
retrieval. The studies we included originated from different countries, some of which 
described systems of free access to TKI medication, and others that did not clarify this. 
However, as all the studies had inclusion criteria that the patient was receiving a TKI 
medication, presumably those patients in the studies all had access to their medication. 
Also, as findings were relatively consistent across studies, we expect our analysis is largely 
transferable to other regions, where patients access TKIs. The synthesis may be limited by 
the exclusion of grey literature and articles not written in the English language, which could 
not be fully searched due to time-constraints; however, the authors were not aware of any 
ongoing work that might impact on study findings.  
Included studies (Table 3) also had limitations. Overall, several lacked a thorough reporting 
of methods, particularly sampling strategies (e.g. inclusion criteria and reporting on excluded 
participants), and in the application of theoretical models to data analysis. For example, Wu 
et al., (2015) used interpretative phenomenological analysis (IPA), but did not describe how 
its features were implemented in the analysis, including the impact of the researchers' own 
conceptions on the findings. Strengths were mostly in the reporting of results. Although this 
varied from descriptive to more conceptual accounts, there was consistency between the 
data and results, quotations were used appropriately, and findings were generally presented 
clearly. 
Regarding clinical implications, unmet need and outcomes can be appropriately measured 
using the CCEQ. Survivorship programmes, individualised and developed for patients with 
CML, would provide the opportunity for discussions about side effects and adherence, 
HQDEOLQJ+&3VWRXQGHUVWDQGWKHSDWLHQW¶VSHUVSHFWLYHDQGXQGHUVWDQGLQJDQGPHHW
educational requirements, as necessary. Such care should be supported by systems that 
allow adequate time and resources for this, with a defined role for primary care HCPs, 
including GPs and practice nurses. Crucially, of greatest value to patients is a caring 
approach among HCPs, supported by the creation and maintenance of a culture of kindness 
and compassion (Campling, 2015).  
Development of survivorship programmes or other interventions to support self-management 
in CML requires further qualitative research to investigate the experiences of those caring for 
people with CML. This should also examine contextual issues for patients, such as social 
support, views on hospital care and disease knowledge. Recent publications have begun to 
emerge that suggest some patients may now safely discontinue TKI medication (Clark et al., 
2017; Etienne et al., 2017; Saussele et al., 2018). Further qualitative research exploring the 
experiences of such patients, alongside the QOL measures used in these studies, will add 
depth to our understanding of this new challenge for patients.  
Conclusion 
This synthesis has demonstrated the significant impact CML and TKI treatment have on 
patient wellbeing and day to day life. As with an increasing number of cancers, CML involves 
the self-management of treatment at home, outside the clinical environment. Our synthesis 
provides evidence that, in the home-setting, patients develop their own strategies to manage 
adherence and side effects, often not discussing this with HCPs. CML self-management 
RFFXUVZLWKLQWKHFRQWH[WRIWKHLQGLYLGXDO¶VRZQNQRZOHGJHDQGSHrceptions of their disease, 
as well as the influence of their HCP and the nuances of the health system providing care. 
As in other chronic cancers, little research exists about experiences and survivorship in 
CML, or the perspectives of HCPs. However, given that treatment is administered at home, 
the development of survivorship programmes or interventions should perhaps look beyond a 
medical model of disease management, to a more a community-based social model, 
delivered with the support of primary care teams, in a setting familiar to patients and where 
they live their lives. Such an approach, which has the capacity to adapt to individual contexts 
and choices, may be most appropriate to develop mechanisms for supporting patient 
decision making and disease management strategies. 
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Table 1 Eligibility criteria 
 
Inclusion  Exclusion  
Participant 
characteristics 
 
CML diagnosis 
$JHG\HDUV 
Males and females 
Chronic phase  
Long-term TKI use (i.e. lifelong)  
Outpatient management 
Any geographical location  
 
$JHG\HDUV 
Accelerated/blast phase  
Receiving end-of-life care 
Not treated with TKIs 
Inpatient management 
 
 
Type of study 
 
Qualitative  Clinical trials/quantitative  
Systematic reviews 
Non-English language 
 
 
 
 
 
 
 
 
 
Table 2: Summary of included studies 
Author/year 
 
Population/country Participants  
(N, age, sex) 
Research question Data collection Research approach/ analysis 
Eliasson et al 2011 CML patients attending hospital, UK N=21 
Age 33-70 
Male 11, Female 10 
To explore the experience of 
CML patients of taking (or not) 
imatinib as prescribed 
 
In-depth unstructured 
interviews 
Constant comparison 
Guilhot et al 2013 CML patients from clinical centres and 
online communities, Brazil, France, 
Germany, Russia and Spain 
N=50 
Age 21-80 
Sex not reported 
To assess the effects of 
diagnosis and treatment on 
patients with CML and offer 
recommendations for HCPs to 
better support patients 
 
In-depth, semi-structured 
interviews with patients 
and relatives. Diary, 
photo journal and 
debriefing interview 
(Brazil and France only) 
Ethnography 
 
Chen et al 2014 CML patients attending an oncology 
outpatient clinic, Southern Taiwan 
N=42 
Age 20-80 
Male 23, Female 19 
dŽĞǆƉůŽƌĞD>ƉĂƚŝĞŶƚƐ ?
experiences of treatment with 
imatinib, and understand 
perceptions, attitudes and 
concerns that may influence 
adherence  
 
Semi-structured 
interviews 
Constant comparison; theme 
saturation 
Wu et al 2015 CML patients and HCPs at a specialist 
cancer centre, Australia 
Patients: N=16 
Age 26-71 
Male 9, Female 7 
Practitioners: N=10 
(4 Haematologists, 3 nurses, 
3 pharmacists) 
To explore and compare patient 
experiences with HCP 
perceptions of imatinib  
Semi-structured 
interviews  
Interpretative phenomenological 
analysis 
Bolarinwa et al 2017 CML patients attending the only 
hospital providing free imatinib, 
Nigeria 
 
N=20 
Age 25 ?56 
Male 10, Female 10 
To evaluate delayed diagnosis, 
health-seeking behaviour, 
medication use and other 
challenges faced by people 
living with CML on imatinib  
 
In-depth semi-structured 
interviews 
Grounded theory (until 
saturation); content analysis of 
themes  
Graffigna et al 2017 CML patients in 22 onco-
haematological centres, Italy 
N=158 
Characteristics not reported 
To reconstruct the subjective 
meaning- process related to 
CML and explore the 
psychological impact of 
suspending therapy 
 
Narrative diaries  Narrative inquiry. Lexicography 
ƐŽĨƚǁĂƌĞĂŶĂůǇƐŝƐĂŶĚĂ “ƉƵƌĞůǇ
ƋƵĂůŝƚĂƚŝǀĞĂŶĂůǇƐŝƐ ?ŽĨ
narratives by hand. 
Lim et al 2017 CML patients at a tertiary care centre, N=13 dŽĞǆƉůŽƌĞƉĂƚŝĞŶƚƐ ? Semi-structured Content analysis  
Northern Malaysia Age 47.8 (mean) 
Male 8, Female 5 
understanding and challenges in 
taking imatinib and nilotinib 
interviews Questionnaire  
Boons et al 2018 
 
 
CML patients from a Dutch advocacy 
group, treated at 9 hospitals, Holland 
N=13 
Age 27-73 
Male 5, Female 8 
To understand reasons for non-
adherence and patient need for 
information and communication 
Semi-structured 
interviews 
Questionnaire 
Mixed methods 
Qualitative thematic framework 
analysis  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Quality appraisal of included articles using Hawker et al (2002) 
Author/year  Abstract/ title Introduction/ aims Methods/ data Sampling Data analysis Ethics/bias Findings Transferability/ generalisability 
Implications/
usefulness 
Eliasson et al 2011 Good Good Fair Fair Fair Fair Good Fair Fair 
Guilhot et al 2013 Good Fair Good Fair Fair Fair Good Fair Fair 
Chen et al 2014 Good Fair Fair Fair Poor Fair Fair Fair Fair 
Wu et al 2015 Fair Good Fair Fair Fair Fair Fair Fair Good 
Bolarinwa et al 2017 Fair Fair Fair Fair Poor Fair Good Fair Fair 
Graffigna et al 2017 Fair Fair Fair Poor Fair Poor Fair Poor Fair 
Lim et al 2017 Good Good Good Fair Poor Fair Fair Good Good 
Tan et al 2017 Good Good Good Fair Fair Fair Good Fair Good 
Boons et al 2018 Fair Fair Fair Fair Poor Fair Good Fair Good 
 
 
Figure 1 Screening process and identification of eligible studies 
 
 
 
 
 
 
 
 
 
Figure 2:  The patient experience of CML in context and over time 
 
